Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

Impel Pharmaceuticals logo

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.04
$0.84
52-Week Range
N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

Remove Ads
Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMPL Stock News Headlines

Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.
Impel Pharmaceuticals Inc. (IMPLQ)
See More Headlines

IMPL Stock Analysis - Frequently Asked Questions

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.42. The firm earned $0.09 million during the quarter.

Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Impel Pharmaceuticals investors own include Athenex (ATNX), NIO (NIO), KLX Energy Services (KLXE), American Airlines Group (AAL), Bolt Biotherapeutics (BOLT), Moderna (MRNA) and Novavax (NVAX).

Company Calendar

Last Earnings
11/15/2021
Today
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMPL
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,310,000.00
Net Margins
-353.93%
Pretax Margin
-353.93%

Debt

Sales & Book Value

Annual Sales
$20.99 million
Price / Cash Flow
N/A
Book Value
($1.86) per share
Price / Book
N/A

Miscellaneous

Free Float
22,418,000
Market Cap
$956,000.00
Optionable
Not Optionable
Beta
1.17
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:IMPL) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners